[{"uuid": "f4396ba4-6cf3-3a41-9c48-3eaefd8b5477", "title": "Cogent Biosciences to Participate in the Guggenheim Biotech Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cogent-biosciences-participate-guggenheim-biotech-130000354.html", "providerPublishTime": 1738242000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4mN81kOyM5UPcWUHobJneg--~B/aD03NzI7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 1860, "height": 772, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1vnYGY3pI5eVQrzZFe4m5g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["COGT"]}, {"uuid": "03cb5401-2e33-3782-b40b-bfa88daae69c", "title": "Cole Pinnow Bought 2,085% More Shares In Cogent Biosciences", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/cole-pinnow-bought-2-085-103512279.html", "providerPublishTime": 1737110112, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["COGT"]}, {"uuid": "4df5a852-ff6f-3310-b46a-8f7e2ccbf292", "title": "This Cogent Biosciences Insider Increased Their Holding By 2,085% Last Year", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/cogent-biosciences-insider-increased-holding-104001630.html", "providerPublishTime": 1737110401, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/dQxIoNx1LKM.kOJYTi633A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["COGT"]}, {"uuid": "f5bdd736-2670-3f2c-8272-9a61307ec395", "title": "Cogent Biosciences Insider Bought Shares Worth $332,413, According to a Recent SEC Filing", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/cogent-biosciences-insider-bought-shares-120640675.html", "providerPublishTime": 1736942800, "type": "STORY"}, {"uuid": "896e04be-8d1e-3e9f-afd4-ad90f37fed13", "title": "Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cogent-biosciences-announces-planned-2025-130000194.html", "providerPublishTime": 1736773200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4mN81kOyM5UPcWUHobJneg--~B/aD03NzI7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 1860, "height": 772, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1vnYGY3pI5eVQrzZFe4m5g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["COGT"]}, {"uuid": "ba7accae-f485-39a5-88f5-789c0dd7e1cf", "title": "Cogent Biosciences Announces Presentation at the 43rd Annual\u00a0J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cogent-biosciences-announces-presentation-43rd-130000327.html", "providerPublishTime": 1736341200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4mN81kOyM5UPcWUHobJneg--~B/aD03NzI7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 1860, "height": 772, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1vnYGY3pI5eVQrzZFe4m5g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["COGT"]}, {"uuid": "7e618cbd-6a7b-3782-98b3-6c872938b793", "title": "Cogent Biosciences Reports Updated Results From Trial of Bezuclastinib", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/cogent-biosciences-reports-updated-results-125636301.html", "providerPublishTime": 1733748996, "type": "STORY"}, {"uuid": "fb9bc316-a1e6-3399-a29b-4e365609a1e8", "title": "Why Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-cogent-biosciences-inc-cogt-180515919.html", "providerPublishTime": 1733335515, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Km3mmAads3jWvPjZAHo_8w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0409cc5623a4ab223b14d4b6a6d2790a", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/8UHyJrZPU1p4AL9eBmOdUQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0409cc5623a4ab223b14d4b6a6d2790a", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "d8bb5fd4-4c66-39cd-97ca-1e88829cd58d", "title": "Needham Downgrades Cogent Biosciences to Hold From Buy", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/needham-downgrades-cogent-biosciences-hold-125745835.html", "providerPublishTime": 1733921865, "type": "STORY"}, {"uuid": "8e97aa1d-3f77-364e-86be-3df87aee2007", "title": "Why Is Cogent Biosciences Stock Trading Higher On Monday?", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/why-cogent-biosciences-stock-trading-175246719.html", "providerPublishTime": 1733766766, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/GP1KRxvg6Eg87yNZ9dWEIw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/a2328af6ca2e3b2df9ccafdcae579695", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/eOIXjhMcqqvw4zgcX5omDg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/a2328af6ca2e3b2df9ccafdcae579695", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "8fef089f-4576-370e-bd69-f83a4121f5a5", "title": "Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cogent-biosciences-announces-positive-updated-170000413.html", "providerPublishTime": 1733677200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4mN81kOyM5UPcWUHobJneg--~B/aD03NzI7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 1860, "height": 772, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1vnYGY3pI5eVQrzZFe4m5g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["COGT"]}, {"uuid": "ae8d0571-ff20-3a36-a355-4a195c0e05c0", "title": "Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cogent-biosciences-announces-updated-clinical-120000992.html", "providerPublishTime": 1733745600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4mN81kOyM5UPcWUHobJneg--~B/aD03NzI7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 1860, "height": 772, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1vnYGY3pI5eVQrzZFe4m5g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/32f4a8977348c1211caa1c1f848d7622", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["COGT"]}]